Latest news with #NewAmsterdam
Yahoo
2 days ago
- Health
- Yahoo
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present full data from the prespecified Alzheimer's Disease (AD) biomarker analyses in the BROADWAY clinical trial (NCT05142722) in a late-breaking oral presentation at the Alzheimer's Association International Conference (AAIC), being held July 30, 2025 in Toronto, Canada. Details of the presentation are as follows: Presentation Title: Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with Cardiovascular DiseaseSession Title: Developing Topics on Innovative Therapeutic ApproachesPresentation Date and Time: Wednesday, July 30, 2025, 8:21-8:28 AM ETPresenter: Philip Scheltens M.D., Room 718 Conference Call and Webcast Information NewAmsterdam will host a live webcast and conference call at 10:00 a.m. ET on July 30, 2025 to review the full AD biomarker data presented at AAIC. The call will include remarks from featured speakers including: Philip Scheltens, M.D., Ph.D., professor of Neurology at the Vrije Universiteit Amsterdam and partner and head of EQT Life Sciences Dementia Fund; Kellyann Niotis, M.D., director of Parkinson's and Lewy Body Dementia Research at The Institute for Neurogenerative Diseases - Parkinson's and Alzheimer's Research Education Foundation; and Nathaniel Chin, M.D., medical director and Clinical Core Co-Leader for the Wisconsin Alzheimer's Disease Research Center (ADRC) and medical director for the Wisconsin Registry for Alzheimer's Prevention (WRAP). To access the live webcast, participants may register here. The live webcast will be available under the 'Events & Presentations' section of the Investor Relations page of the Company's website at To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam's website following the live event. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactReal Chemistry on behalf of NewAmsterdamChristian EdgingtonP: 1-513-310-6410cedgington@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mirror
12-07-2025
- Entertainment
- Daily Mirror
'Hidden gem' medical drama that had fans 'hooked' now streaming on Prime Video
All five seasons of a hit US medical drama are now available to stream on the platform A "hidden gem" medical drama that had fans "hooked" is now streaming on Prime Video. Based on Eric Manheimer's 2012 memoir, New Amsterdam follows the journey of Dr Max Goodwin (played by Ryan Eggold) as he takes on the role of medical director at one of America's oldest public hospitals. In his new position, Max is determined to overhaul the neglected institution, cutting through red tape to deliver outstanding care to patients. The series, which debuted in 2018, also features Freema Agyeman, Janet Montgomery, Jocko Sims, Anupam Kher, Tyler Labine and Sandra Mae Frank. After a successful four-year run on NBC, it was revealed in 2022 that the show would conclude with its fifth season, comprising 13 episodes, reports Surrey Live. New Amsterdam can already be streamed in its entirety on Netflix, Sky and NOW, but now all five seasons have been added to Prime Video as well. If you're new or haven't held a Prime membership for a full year, you can get a 30-day free trial of the complete Prime service (not just Prime Video) directly from Amazon. Pricing in the UK stands at £8.99 per month or £95 per year. To enjoy the premium ad-free service, you'll need to shell out an additional £2.99 per month. Throughout its original run, New Amsterdam garnered mixed reviews from critics, who felt the show didn't push any boundaries. However, its audience was much more enthusiastic, with many preferring the drama over its medical rival Grey's Anatomy. "I was impressed by the social commentary in the writing! Well acted. All the usual obvious stuff but a few hidden gems for the few who still want to enjoy a show about life," one viewer penned on IMDb. Another chimed in: "This show looks at the human side of medicine and that is refreshing. In my opinion, it's better than Grey's Anatomy." A third shared: "Finally a medical drama without the usual drama. It's not about the endless romance between the doctors and nurses, it is really focused about the medical aspect of the hospital. The characters are very refreshing and particularly Ryan Eggold is so endearing in his first remarkable role." Echoing the sentiment, a fourth fan wrote: "One of the best medical dramas I've seen. It had me hooked from the first episode."
Yahoo
09-07-2025
- Entertainment
- Yahoo
Outback Steakhouse Makes a Splash with Return of the Aussie JAWSsie Cocktail and New Mocktail
Outback dives into summer with fin-credible deals including cocktails starting at $8 and 50% off all Aussie-tizers TAMPA, Fla., July 9, 2025 /PRNewswire/ -- Outback Steakhouse is diving into summer with the return of its wildly popular Aussie JAWSsie – a fin-tastic beverage that first made waves across social media for its dangerously delicious flavor and interactive, shark-themed presentation. Crafted with New Amsterdam® Raspberry Vodka, Blue Curacao, a trio of citrus juices, and a dose of grenadine, the Aussie JAWSsie is back for a limited time only, now through the end of summer. For those looking to swim in booze-free waters, Outback is also offering the Sharkey Temple – a playful, punchy mix of Sprite and grenadine. Both are served with a keepsake shark that pours grenadine from its mouth, creating a playful burst of color. But the JAWS-dropping fun doesn't stop there. Aussie JAWSsie Takeovers are happening at select Outback locations during the popular week when sharks hit the small screen, July 14–17 and July 21–24 (Monday–Thursday only from 4 to 6 p.m.). Guests can sink their teeth into shark-themed vibes in the bar area while enjoying: The Aussie JAWSsie for only $8.99 50% off all Aussie-tizers from the iconic Bloomin' Onion to the new Fried Mozzarella Bloomerangs $8 classic cocktails (available all day) Exclusive bar-only fun and themed décor Download the Outback app to RSVP Whether you're a cocktail connoisseur or just in it for the shark bait, the Aussie JAWSsie is your go-to drink of the summer. Don't miss the frenzy — available for a limited time only at participating Outback Steakhouse locations. Follow Outback on Instagram and TikTok to join the fun. Price, product, and participation may vary. About Outback Steakhouse®:There's a special spirit at Outback Steakhouse®. One where mates gather, stories are exchanged, and steakhouse favorites flow as freely as the conversation. Serve it up with a dash of Aussie hospitality, and you've got all the makings of a great experience you'll want to share with your friends, time and time again. We're known for high quality, juicy steaks with your choice of big cuts and bold flavor, cooked just the way you like it. Spirited drinks that start the night off right and a heap of craveable dishes and fan favorites like our iconic Bloomin' Onion. For more information, please visit or follow Outback on Instagram, TikTok and Facebook. Media Contact: Kellyn Curtis, View original content to download multimedia: SOURCE Outback Steakhouse Sign in to access your portfolio
Daily Record
09-07-2025
- Entertainment
- Daily Record
Netflix's The Resident fans urged to watch medical drama as it lands on UK streamer
The medical drama is now available to stream in the UK Fans of Netflix's The Resident are being urged to watch a medical drama that has finally landed on the UK streaming service. New Amsterdam, which ran from 2018 to 2022, follows a medical director at one of America's oldest public hospitals. Ryan Eggold takes on the role of doctor Max Goodwin as he sets out to make a change at the neglected and outdated facilities. IMDB teases: "A new medical director breaks the rules to heal the system at America's oldest public hospital." And now, the series has found a new home in the UK as it is available to stream on Netflix. New Amsterdam is also available to watch on Prime Video as well as NOW TV. A Netflix synopsis reads: "Medical director Dr Max Goodwin fires a whole surgical unit as his first task at a storied public hospital. His second task is to ask, 'How can I help?'" First released in America in 2018, the show ran for five seasons before coming to an end in 2023. And it was a hit with fans. Over on IMDB one person wrote: "Finally a medical drama without the usual drama. It's not about the endless romance between the doctors and nurses, it's not focused on the sexual perks and pains of the staff's sexual life, it is really focused about the medical aspect of the hospital." Another said: "Best new show I've seen. Interesting storylines and tear jerking. Ryan Eggold is outstanding." A third commented: "This show conjured fond memories of ER and House. Ryan Eggold is riveting! He brings complexity to both the show and his character - so passionate, determined and vulnerable. The rest of the cast are great as well." On Google reviews, another penned: "I'm not usually into doctor shows and could never get into Grey's Anatomy, but I absolutely LOVE this show, and adore Ryan Eggold as Max. "He brings so much depth, heart, conflict, comedy, passion, charm, and charisma to the role and is hard not to fall in love with immediately." Another said: "Loved every series. What a smashing show." Dubbed the perfect show for fans of medical dramas like The Resident, fans will also see Jocko Sims as Dr Floyd Reynolds, Freema Agyeman as Dr Helen Sharpe and Janet Montgomery as Dr Lauren Bloom.
Fast Company
18-06-2025
- Automotive
- Fast Company
Should drivers be forced to go slower?
It's been almost 400 years since the leaders of New Amsterdam (now New York City) confronted a growing threat on their streets: people moving too fast. In 1652, the colonial council passed what may be North America's first speed limit: 'No wagons, carts or sleighs shall be run, rode or driven at a gallop within this city of New Amsterdam,' with Broadway (then a commercial corridor) as the lone exception. Violators were fined the equivalent of $150 to $200 in today's dollars, and repeat offenders could face corporal punishment. European settlers understood that speed in a dense environment is a recipe for disaster. In the 1780s, engineer James Watt used spinning flyweights to automatically regulate his steam engines to keep them from running too fast. This low-tech speed limiter became the blueprint for other automotive safety mechanisms. In 1901, the British Wilson-Pilcher car came equipped with a mechanical governor, limiting how fast the engine could rev. It was one of the first consumer automobiles to feature speed-limiting technology, and almost a century before modern cruise control. In 1923, Cincinnati nearly became the first U.S. city to require speed governors on all vehicles, but the proposal to cap speeds at 25 MPH failed. Auto industry lobbyists warned that mechanical limiters would reduce car sales and infringe on driver freedom. So-called Motordom still holds to that defensive position, but they've expanded their propaganda to dismiss speed as a problem, or as you see in many car commercials, embrace speed as something their product delivers. Drivers are forcing the government to put its foot down When modern Americans are faced with a conversation about taking a foot off the gas, they tend to react by pressing their hands against their ears and giving a 'la-la-la-la-la, I cannot hear you, speeding is fine.' The problem is, most people don't understand the dangers of driving fast in populated areas like cities and suburbs. Because they don't understand the connection between speed and safety, it's only natural that they'll claim speed limiting devices are just another case of an authoritative government, elitist central planning, nanny state overreach, etc. The comments below followed a March 27, 2025 Washington Post article, and they're hardly outliers on this topic: 'Another step to enslavement.' 'The nanny state rides yet again.' 'Big brotherism at its worst.' 'So anyone late to an appointment has no way to get the car moving a little faster. That sounds like a grim future, particularly since so many speed limits are set pathetically low!' Technology that's used to change driver behavior comes down to this fundamental issue: licensed drivers routinely choose not to govern themselves, demonstrating a need to be governed by an outside force. I don't like that we find ourselves in a situation where doors are opened for government authorities to force companies how to make a product. But we don't have to invite or even demand action by state and federal agencies if we (anyone who ever drives a motor vehicle) would simply behave better behind the wheel. Speed ruins far more lives than we'll ever know It's widely known among transportation professionals that police reports focus on issues other than speed even when speed causes a calamity. For example, if someone is driving 40 MPH on a city street, and a driver who was texting says the pedestrian 'came out of nowhere,' this is not classified by police as speed being a factor. But speed was a fundamental factor if the driver didn't see or react in time to stop for the pedestrian. In the US, about 16 million people smashed their cars into each other last year, sending roughly 40,000 people to the morgue and another 2.5 million to emergency rooms. Speed is a fundamental factor in severe traffic crashes, regardless of what the police report says. Speed matters because it amplifies mistakes People will always make mistakes, but the most consequential driving errors are amplified with increased speed. Mistakes like being distracted by a child in the backseat and drifting into another lane quickly elevate the risk to the driver, passengers, and anyone else nearby when going fast. Three important things are much safer on city streets at 25 MPH than 40 MPH: What you see. Your field of view (what engineers call the cone of vision) shrinks as you accelerate, meaning you no longer clearly see the sidewalks, pedestrians, dogs, drivers about to leave a parked car, someone about to run a red light on a cross-street, etc. When you react. You don't have as much time to react to any of the events listed above. In one second, you travel about 2 car lengths at 25 MPH, but 4 car lengths at 40 MPH. That's just one second. Think about how often drivers fiddle with their phone for one Mississippi, two Mississippi, three Mississippi. Where you stop. Even under ideal weather and pavement conditions, the moment you spot a potential danger and hit the brakes, it takes a lot more distance to stop from 40 MPH than 25 MPH. The difference between 165 feet and 85 feet can be the difference between a dead pedestrian and a close call. Speed matters because it makes crashes more severe In addition to making crashes more likely to occur, high-speed driving also increases the amount of carnage in crashes. Physics explains: [crash energy = (½) × (mass) × (speed²)]. That squared value is everything. When you double your driving speed, the crash energy quadruples. Even a small speed increase like 5 or 10 MPH greatly magnifies the force of impact. Despite decades of signage and PSAs, people keep driving too fast in the exact places where caution matters most: neighborhoods, school zones, commercial districts, and crosswalks. Technology exists to govern people who refuse to govern themselves. But I'm hoping you don't force the hands of lawmakers. Instead, I hope you (and everyone else operating a motor vehicle) will slow down in populated areas.
